CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03679624
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:30.763875+00:00
Published At: 2023-10-23T00:00:00+00:00
Record Updated At: 2023-10-23
Results Posted At: 2023-10-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Waldenstrom Macroglobulinemia", "Waldenstrom\u0027s Disease", "Waldenstr\u00f6m; Hypergammaglobulinemia", "Waldenstrom\u0027s Macroglobulinemia Recurrent", "Waldenstrom\u0027s Macroglobulinemia of Lymph Nodes", "Waldenstrom\u0027s Macroglobulinaemia, Without Mention of Remission", "Waldenstrom\u0027s Macroglobulinemia Refractory"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-10-23"
protocolSection.identificationModule.nctId: "NCT03679624"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstr\u04e7m\u0027s Macroglobulinemia"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-10-23"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.